These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12898039)

  • 1. [Familial versus sporadic prostate cancer in the German population. Clinical and pathological characteristics in patients after radical prostatectomy].
    Paiss T; Bock B; Gschwend JE; Heinz H; Vogel W; Kron M; Hautmann RE; Herkommer K
    Urologe A; 2003 Jul; 42(7):946-53. PubMed ID: 12898039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy.
    Paiss T; Herkommer K; Bock B; Heinz H; Vogel W; Kron M; Kuefer R; Hautmann RE; Gschwend JE
    Eur Urol; 2003 Jun; 43(6):615-21. PubMed ID: 12767361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
    Siddiqui SA; Sengupta S; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2006 Sep; 176(3):1118-21. PubMed ID: 16890705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of patients with familial versus sporadic prostate cancer.
    Roehl KA; Loeb S; Antenor JA; Corbin N; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 1):2438-42; discussion 2442. PubMed ID: 17085123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
    Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
    World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological features of hereditary prostate cancer.
    Keetch DW; Humphrey PA; Smith DS; Stahl D; Catalona WJ
    J Urol; 1996 Jun; 155(6):1841-3. PubMed ID: 8618269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute.
    Guillonneau B; el-Fettouh H; Baumert H; Cathelineau X; Doublet JD; Fromont G; Vallancien G
    J Urol; 2003 Apr; 169(4):1261-6. PubMed ID: 12629339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
    Huang SP; Huang CY; Wu WJ; Pu YS; Chen J; Chen YY; Yu CC; Wu TT; Wang JS; Lee YH; Huang JK; Huang CH; Wu MT
    Int J Cancer; 2006 Oct; 119(8):1902-7. PubMed ID: 16708371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
    Reis ST; Viana NI; Leite KR; Diogenes E; Antunes AA; Iscaife A; Nesrallah AJ; Passerotti CC; Srougi V; Pontes-Junior J; Salles ME; Nahas WC; Srougi M
    PLoS One; 2016; 11(12):e0166380. PubMed ID: 27906997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].
    Herkommer K; Paiss T; Merz M; Gschwend JE; Kron M
    Urologe A; 2006 Dec; 45(12):1532-9. PubMed ID: 17004091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.